What spectrophotometric interference from hemolysis, icterus, and lipemia can affect automation results and how is it mitigated?

Prepare for the Clinical Chemistry Automation Test with a comprehensive practice quiz. Study with detailed explanations and multiple choice questions to enhance your understanding and boost your confidence. Ace your exam with our prepared material!

Multiple Choice

What spectrophotometric interference from hemolysis, icterus, and lipemia can affect automation results and how is it mitigated?

Spectrophotometric assays rely on measuring how much light a sample absorbs at a specific wavelength to quantify an analyte. When hemolysis, icterus, or lipemia are present, they change the sample’s optical properties—hemoglobin from red blood cell rupture, bilirubin giving a yellow color, and lipids causing turbidity and light scattering. Those changes add or alter absorbance in ways that can be mistaken for the analyte signal, leading inaccurate results. Mitigation strategies are built into many automated systems. Spectral correction uses measurements at multiple wavelengths to separate the true analyte signal from the interfering components, effectively subtracting the interference. Sample indexing provides an interference assessment (an HIL index) that flags or adjusts results, guiding whether a correction is applied or a recollection is needed. Alternative methods or assays that are less sensitive to these interferences can be chosen, such as using a different analytical principle or wavelength. If the interference is too great, recollecting a new sample is often the most reliable option. The other choices are not correct because interference from these factors does affect absorbance, and it’s not limited to lipemia alone. Recalibration of the instrument alone does not remove the specific absorbance or scattering caused by HIL factors.

Spectrophotometric assays rely on measuring how much light a sample absorbs at a specific wavelength to quantify an analyte. When hemolysis, icterus, or lipemia are present, they change the sample’s optical properties—hemoglobin from red blood cell rupture, bilirubin giving a yellow color, and lipids causing turbidity and light scattering. Those changes add or alter absorbance in ways that can be mistaken for the analyte signal, leading inaccurate results.

Mitigation strategies are built into many automated systems. Spectral correction uses measurements at multiple wavelengths to separate the true analyte signal from the interfering components, effectively subtracting the interference. Sample indexing provides an interference assessment (an HIL index) that flags or adjusts results, guiding whether a correction is applied or a recollection is needed. Alternative methods or assays that are less sensitive to these interferences can be chosen, such as using a different analytical principle or wavelength. If the interference is too great, recollecting a new sample is often the most reliable option.

The other choices are not correct because interference from these factors does affect absorbance, and it’s not limited to lipemia alone. Recalibration of the instrument alone does not remove the specific absorbance or scattering caused by HIL factors.

More practice questions